ADVFN US – Market Content Editor

American Fusion (USOTC:AMFN) has appointed Asian financial markets and digital-assets executive Samson Lee as an independent director, adding capital-markets, corporate governance and international business experience as the fusion-energy developer evaluates longer-term opportunities across Asia. The Samson Lee appointment expands American Fusion’s board expertise beyond energy technology and comes as the company pursues its planned progression…

Anavex Life Sciences (NASDAQ:AVXL) has mailed a letter urging shareholders to vote for all six of its director nominees ahead of the company’s September 24 annual meeting, highlighting their experience across drug development, healthcare, capital allocation, finance and regulatory affairs. The Anavex director vote puts corporate governance in focus ahead of the meeting, with the…

Impact Fusion International (USOTC:IFUS) has expanded production capacity at its Napoleonville, Louisiana facility with the installation of a retrofitted Selco/Mosley Badger Double Ram Press, targeting higher output and lower production costs as customer demand and back orders increase. The production expansion is expected to give IFUS initial capacity of 600 bales per day while using…

Green Leaf Innovations (USOTC:GRLF) has outlined plans for a luxury cigar and e-commerce expansion that will add a new premium cigar range, branded accessories and a members-only online sales platform as the company seeks to broaden its consumer-products business. The strategy follows Green Leaf Innovations’ recently announced Letter of Intent to acquire a 25% equity…

HydroGraph Clean Power (USOTC:HGRAF) will ask shareholders to approve a proposed U.S. redomiciling transaction at a special meeting scheduled for October 29, 2026, as the graphene producer seeks to align its corporate structure with its expanding U.S. operations and shareholder base. The proposed U.S. redomiciling remains subject to shareholder, regulatory, court and other required approvals,…

INVO Fertility (NASDAQ:IVF) reported a 17% increase in second-quarter 2026 revenue to $2.18 million as the first full-quarter contribution from Family Beginnings and growth initiatives across its existing clinics expanded the fertility services platform. Clinic-level Adjusted EBITDA increased to approximately $333,000 from $164,000 in Q1, but consolidated Adjusted EBITDA remained negative at $1.0 million, highlighting…

Generation Income Properties (NASDAQ:GIPR) narrowed its second-quarter 2026 net loss attributable to common shareholders by 76% year over year and regained compliance with Nasdaq’s stockholders’ equity requirement as asset sales, capital raising and preferred equity restructuring strengthened its balance sheet. The Q2 results show measurable progress in GIPR’s deleveraging strategy, but near-term risks remain, including…

EyePoint (NASDAQ:EYPT) reported that its Phase 3 LUGANO trial of DURAVYU in wet age-related macular degeneration did not achieve its primary endpoint in the full dataset, although the company reported positive secondary outcomes and an ad hoc analysis in which DURAVYU was non-inferior to aflibercept. The Phase 3 LUGANO trial result puts added importance on…

NEXGEL (NASDAQ:NXGL) reported second-quarter 2026 revenue of $3.69 million and a net loss of $2.87 million as the healthcare products company worked through a slower-than-expected integration and commercial rollout of its newly formed BioNX Surgical division. The Q2 results highlight a transition period following NEXGEL’s April transaction with Celularity, with supply constraints contributing to a…

argenx (NASDAQ:ARGX) reported positive topline results from its Phase 3 ALKIVIA trial of VYVGART Hytrulo in adults with autoimmune myositis, with the study meeting its primary endpoint in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population. The Phase 3 ALKIVIA trial produced a statistically significant 15.4-point treatment advantage over placebo in mean Total…